Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder Biopharmaceuticals (NASDAQ:ALDR)

Alder Biopharmaceuticals logoAlder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDR
  • CUSIP: N/A
  • Web: www.alderbio.com
Capitalization:
  • Market Cap: $814.12 million
  • Outstanding Shares: 50,410,000
Average Prices:
  • 50 Day Moving Avg: $19.62
  • 200 Day Moving Avg: $22.10
  • 52 Week Range: $16.00 - $36.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.03
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: $112,999.00
  • Price / Sales: 7,204.68
  • Book Value: $5.71 per share
  • Price / Book: 2.83
Profitability:
  • EBIDTA: ($223,700,000.00)
  • Return on Equity: -32.77%
  • Return on Assets: -31.60%
Debt:
  • Current Ratio: 25.55%
  • Quick Ratio: 25.50%
Misc:
  • Average Volume: 595,725 shs.
  • Beta: 2.61
  • Short Ratio: 15.29
 

Frequently Asked Questions for Alder Biopharmaceuticals (NASDAQ:ALDR)

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its earnings results on Thursday, April, 27th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $1.04. During the same period in the previous year, the company posted ($0.76) EPS. View Alder Biopharmaceuticals' Earnings History.

When will Alder Biopharmaceuticals make its next earnings announcement?

Alder Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for Alder Biopharmaceuticals.

Where is Alder Biopharmaceuticals' stock going? Where will Alder Biopharmaceuticals' stock price be in 2017?

9 analysts have issued 1 year target prices for Alder Biopharmaceuticals' stock. Their forecasts range from $36.00 to $47.00. On average, they expect Alder Biopharmaceuticals' stock price to reach $41.44 in the next twelve months. View Analyst Ratings for Alder Biopharmaceuticals.

What are analysts saying about Alder Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:

  • 1. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)
  • 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (2/16/2017)

Who are some of Alder Biopharmaceuticals' key competitors?

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the folowing people:

  • Stephen M. Dow, Independent Chairman of the Board
  • Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director
  • Larry K. Benedict, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
  • Randal A. Hassler, Senior Vice President - Pharmaceutical Operations
  • Jeffrey T.L. Smith M.D., Senior Vice President, Translational Medicine
  • John A. Latham Ph.D., Chief Scientific Officer
  • Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary
  • Wendy L. Yarno, Director
  • Paul Rutherford Carter, Independent Director
  • Paul B. Cleveland, Independent Director

Who owns Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), Janus Capital Management LLC (10.25%), Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), Redmile Group LLC (3.79%) and State Street Corp (3.53%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Larry Benedict, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.

Who sold Alder Biopharmaceuticals stock? Who is selling Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Eventide Asset Management LLC, Alliancebernstein L.P., Morgan Stanley, Iguana Healthcare Management LLC, JPMorgan Chase & Co., Ameriprise Financial Inc. and Foresite Capital Management II LLC. Company insiders that have sold Alder Biopharmaceuticals stock in the last year include Jeffrey T L Smith, John A Latham, Mark James Litton and Randall C Schatzman. View Insider Buying and Selling for Alder Biopharmaceuticals.

Who bought Alder Biopharmaceuticals stock? Who is buying Alder Biopharmaceuticals stock?

Alder Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Citadel Advisors LLC, Pictet Asset Management Ltd., Janus Capital Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc. and AXA. View Insider Buying and Selling for Alder Biopharmaceuticals.

How do I buy Alder Biopharmaceuticals stock?

Shares of Alder Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alder Biopharmaceuticals' stock price today?

One share of Alder Biopharmaceuticals stock can currently be purchased for approximately $16.15.


MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alder Biopharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $41.44 (156.62% upside)

Analysts' Ratings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Needham & Company LLCInitiated CoverageBuy -> Buy$36.00MediumView Rating Details
4/25/2017AegisReiterated RatingBuy$41.00MediumView Rating Details
4/17/2017Jefferies Group LLCReiterated RatingBuy$43.00LowView Rating Details
12/18/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
12/9/2016BMO Capital MarketsReiterated RatingOutperform$42.00N/AView Rating Details
11/25/2016Piper Jaffray CompaniesSet Price TargetBuy$47.00N/AView Rating Details
11/22/2016Credit Suisse Group AGReiterated RatingBuy$38.00N/AView Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00N/AView Rating Details
9/13/2016JPMorgan Chase & Co.Initiated CoverageOverweight$40.00N/AView Rating Details
4/21/2016Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/30/2015 forward)

Earnings

Earnings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Earnings by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)
Earnings History by Quarter for Alder Biopharmaceuticals (NASDAQ ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2017        
4/27/2017Q1 2017($0.95)($1.99)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.90)($0.97)ViewN/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.40)ViewListenView Earnings Details
3/4/2015Q414($0.18)($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.22)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/20/2014Q1($0.22)($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)
2017 EPS Consensus Estimate: ($3.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.98)($0.86)($0.92)
Q2 20172($1.02)($0.85)($0.94)
Q3 20172($1.02)($0.91)($0.97)
Q4 20172($1.02)($0.99)($1.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alder Biopharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 11.50%
Insider Trades by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)
Institutional Ownership by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)
Insider Trades by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.00View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.00View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.00View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alder Biopharmaceuticals (NASDAQ:ALDR)
Latest Headlines for Alder Biopharmaceuticals (NASDAQ:ALDR)
Source:
DateHeadline
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 23 at 4:16 PM
seekingalpha.com logoAlder Biopharmaceuticals (ALDR) Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 23 at 7:10 AM
finance.yahoo.com logoLilly's Migraine Drug Phase III Trials Meet Primary Endpoint
finance.yahoo.com - May 16 at 7:07 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - May 15 at 5:42 PM
finance.yahoo.com logoLilly migraine treatment meets main goal in late-stage studies
finance.yahoo.com - May 12 at 4:01 PM
finance.yahoo.com logoAlder BioPharmaceuticals® to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 9:23 AM
finance.yahoo.com logoAlder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALDR-US : May 8, 2017
finance.yahoo.com - May 8 at 11:13 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Expected to Announce Earnings of -$1.71 Per Share
www.americanbankingnews.com - May 5 at 7:52 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Egalet, Argos Therapeutics, Alder Biopharma, and Anavex Life Sciences - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:29 PM
seekingalpha.com logoWhy Alder Biopharmaceuticals Is Down - And What To Do About It ... - Seeking Alpha
seekingalpha.com - May 3 at 8:31 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - May 3 at 10:21 AM
streetinsider.com logoAlder BioPharma (ALDR) Announces Positive Phase 2b Study Data for Eptinezumab at AAN Meeting - StreetInsider.com
www.streetinsider.com - April 30 at 4:46 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Receiving Negative News Coverage, Report Finds
www.americanbankingnews.com - April 30 at 7:49 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 6:42 PM
streetinsider.com logoAlder BioPharma (ALDR) Announces Positive Phase 2b Study Data for Eptinezumab at AAN Meeting
www.streetinsider.com - April 28 at 4:24 PM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Releases Quarterly Earnings Results, Misses Estimates By $1.04 EPS
www.americanbankingnews.com - April 27 at 10:27 PM
finance.yahoo.com logoAlder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
finance.yahoo.com - April 27 at 8:53 PM
finance.yahoo.com logoAlder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : April 27, 2017
finance.yahoo.com - April 27 at 8:53 PM
finance.yahoo.com logoAlder BioPharmaceuticals posts 1Q loss
finance.yahoo.com - April 27 at 8:53 PM
finance.yahoo.com logoInvestor Network: Alder Biopharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - April 27 at 3:49 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 2:35 PM
finance.yahoo.com logoAlder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : April 26, 2017
finance.yahoo.com - April 26 at 3:39 PM
globenewswire.com logoAlder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American ... - GlobeNewswire (press release)
globenewswire.com - April 25 at 8:31 AM
streetinsider.com logoAlder BioPharma (ALDR) Reports Additional Data from Eptinezumab Development Program at AAN Conference - StreetInsider.com
www.streetinsider.com - April 24 at 3:28 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Earning Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 24 at 12:19 PM
finance.yahoo.com logoAlder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting
finance.yahoo.com - April 24 at 10:49 AM
globenewswire.com logoAlder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results - GlobeNewswire (press release)
globenewswire.com - April 21 at 3:29 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 10:07 AM
finance.yahoo.com logoAlder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results - Yahoo Finance
finance.yahoo.com - April 20 at 3:31 PM
finance.yahoo.com logoAlder BioPharmaceuticals to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results
finance.yahoo.com - April 20 at 3:31 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Receiving Positive News Coverage, Study Finds
www.americanbankingnews.com - April 18 at 11:02 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - April 17 at 7:14 PM
americanbankingnews.com logoAlder Biopharmaceuticals (ALDR) Given Daily News Sentiment Score of 0.07
www.americanbankingnews.com - April 14 at 3:54 PM
americanbankingnews.com logo Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) Will Announce Earnings of -$0.95 Per Share
www.americanbankingnews.com - April 14 at 8:04 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - April 10 at 9:22 AM
americanbankingnews.com logoShort Interest in Alder Biopharmaceuticals Inc (ALDR) Increases By 1.6%
www.americanbankingnews.com - April 8 at 12:50 PM
seekingalpha.com logoAlder Biopharmaceuticals (ALDR) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 3:28 PM
finance.yahoo.com logoAlder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors
finance.yahoo.com - April 7 at 7:49 AM
americanbankingnews.com logoAlder Biopharmaceuticals Inc (ALDR) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 6 at 1:34 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Alder Biopharmaceuticals Inc (ALDR)
www.americanbankingnews.com - March 30 at 8:54 PM
finance.yahoo.com logoAlder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 9:03 AM
streetinsider.com logoAlder BioPharma (ALDR) Announces Presentations AAN Meeting Supporting Development of Eptinezumab for ... - StreetInsider.com
www.streetinsider.com - March 7 at 5:25 AM
globenewswire.com logoAlder BioPharmaceuticals Announces Presentations at 69th Annual American ...
globenewswire.com - March 6 at 11:19 AM
finance.yahoo.com logoAlder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention
finance.yahoo.com - March 6 at 11:19 AM
finance.yahoo.com logoALDER BIOPHARMACEUTICALS INC Financials
finance.yahoo.com - March 1 at 3:25 PM
biz.yahoo.com logoALDER BIOPHARMACEUTICALS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - February 24 at 11:07 AM
us.rd.yahoo.com logoAlder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results
us.rd.yahoo.com - February 24 at 11:07 AM
us.rd.yahoo.com logo4:16 pm Alder BioPharmaceuticals reports Q4 results
us.rd.yahoo.com - February 24 at 11:07 AM
biz.yahoo.com logoALDER BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
us.rd.yahoo.com - February 24 at 11:07 AM
finance.yahoo.com logoEdited Transcript of ALDR earnings conference call or presentation 23-Feb-17 10:00pm GMT
finance.yahoo.com - February 24 at 11:07 AM

Social

Chart

Alder Biopharmaceuticals (ALDR) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by MarketBeat.com Staff